AVONEX 30 MCG / 0.5 ML — DIN 02269201
INTERFERON BETA-1A : 30 MCG / 0.5 ML · BIOGEN CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is AVONEX?
AVONEX 30 MCG / 0.5 ML contains INTERFERON BETA-1A : 30 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02269201, held by BIOGEN CANADA INC, supplied as SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 02-Dec-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AVONEX used for?
Relapsing forms of MS to slow disability, decrease exacerbations, and reduce brain lesions; also for single demyelinating events with abnormal MRI to delay clinically definite MS.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Interferon Beta-1a cost around the world?
Interferon Beta-1a is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Austria | KVP (Kassenverkaufspreis) | 8 | 8 |
| South Africa | single exit price | 5 | 7 |
| Czechia | max producer price (ex-factory) | 2 | 6 |
| Luxembourg | reimbursement | 6 | 6 |
| Morocco | PPV (public price) | 4 | 6 |
| Saudi Arabia | public | 5 | 5 |
| Bahrain | retail (max) | 2 | 3 |
| United Arab Emirates | public | 2 | 2 |
| Hungary | producer price (ex-factory) | 2 | 2 |
45 pack listings across 36 brand entries and 8 price bases, refreshed 05 Sep 2026. Ranges span every Interferon Beta-1a pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Interferon Beta-1a in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Interferon Beta-1a, across 11 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| EMD SERONO, A DIVISION OF EMD INC., CANADA | 8 | 4 | REBIF | Sourceable in Canada |
| BIOGEN CANADA INC | 3 | 1 | AVONEX | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 30 MCG / 0.5 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAMUSCULAR |
| Pack configuration (monograph) | Package containing 4 dose administration packs (prefilled syringe or autoinjector) and an accessory pouch with alcohol wipes, gauze pads, and adhesive bandages. |
| Storage | Not explicitly detailed in the provided text snippet (Section 11 mentioned in TOC but content not provided), though typically refrigerated. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Interferon Beta-1a |
|---|---|
| ATC code | L03AB07 |
| AHFS class | 92:20.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02269201 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2269201 |
| Brand name | AVONEX |
| Generic / active ingredient | INTERFERON BETA-1A : 30 MCG / 0.5 ML |
| Market authorization holder | BIOGEN CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | L03AB07 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L03AB |
| Current status | MARKETED |
| Status date | 02-Dec-2005 |
| Original market date | 2005-12-02 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
30 μg injected intramuscularly once per week. Titration may start at 7.5 μg/week, increasing by 7.5 μg each week until full dose. Antipyretic analgesics advised to reduce flu-like symptoms.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to natural or recombinant interferon beta, or any other component of the formulation.
Warnings and precautions
Risk of severe liver injury, depression/suicidal ideation, decreased blood counts, seizures, thrombotic microangiopathy (TMA), and anaphylaxis. Monitor cardiac patients closely.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 11 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| REBIF | 44 MCG / 0.5 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | MARKETED | 02237320 |
| REBIF | 66 MCG / 1.5 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | MARKETED | 02318253 |
| REBIF | 132 MCG / 1.5 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | MARKETED | 02318261 |
| REBIF | 22 MCG / 0.5 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | MARKETED | 02237319 |
| AVONEX | 1.1 ML | POWDER FOR SOLUTION | BIOGEN CANADA INC | CANCELLED POST MARKET | 02237770 |
| AVONEX | 60 MCG | POWDER FOR SOLUTION | BIOGEN CANADA INC | APPROVED | 02267594 |
| REBIF | 132 MCG / 1.5 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | CANCELLED PRE MARKET | 02318288 |
| REBIF | 8.8 MCG / 0.2 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | CANCELLED POST MARKET | 02277492 |
| REBIF | 8.8 MCG / 0.2 ML | POWDER FOR SOLUTION ; KIT ; LIQUID | EMD SERONO, A DIVISION OF EMD INC., CANADA | CANCELLED POST MARKET | 02281708 |
| REBIF | 2 ML | LIQUID ; KIT ; POWDER | EMD SERONO, A DIVISION OF EMD INC., CANADA | CANCELLED POST MARKET | 02237317 |
2 · Same class — other molecules in ATC L03AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Interferon Beta-1a | AVONEX · REBIF | 11 | 5 | Yes |
| Peginterferon Beta-1a | PLEGRIDY | 4 | 2 | Yes |
| Interferon Beta-1b | BETASERON · EXTAVIA | 2 | 1 | Yes |
| Peginterferon Alfa-2a | PEGASYS | 2 | 1 | Yes |
| Peginterferon Alfa-2b, Combinations | PEGETRON · REBETRON READY TO USE SOLUTION (ALBUMIN(HUMAN)FREE) (6000000 IU/ML AND 200MG CAPSULES) · REBETRON SOLUTION (ALBUMIN (HUMAN) FREE) (18 MIU MULTI-DOSE PEN / 200MG CAPSULES) · VICTRELIS TRIPLE | 15 | 0 | Not in Canada |
| Interferon Alfa-2b | INTRON A · INTRON A - KIT (PWS+DILUENT) 3000000IU/VIAL · INTRON A - KIT (PWS+DILUENT) 5000000IU/VIAL · INTRON A - LIQ 5000000IU/ML · +3 more | 13 | 0 | Not in Canada |
| Interferon Alfa-2a | ROFERON A SOLN INJ 6 MILLION · ROFERON A STERILE PWS 18M UNIT/VIAL · ROFERON A STERILE PWS 3M UNIT/VIAL · ROFERON A STERILE PWS 9M UNIT/VIAL · +8 more | 12 | 0 | Not in Canada |
| Peginterferon Alfa-2b | UNITRON PEG | 4 | 0 | Not in Canada |
| Peginterferon Alfa-2a, Combinations | PEGASYS RBV | 2 | 0 | Not in Canada |
| Interferon Alfa-N1 | WELLFERON INJ 10 000 000UNIT/ML · WELLFERON INJ 3000000UNIT/ML | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L03AA | Ancestim · Filgrastim · Pegfilgrastim | 24 | 21 |
| L03AX | Bcg Vaccine · Glatiramer Acetate · Melanoma Vaccine · Plerixafor | 18 | 8 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is AVONEX called?
The same molecule, Interferon Beta-1a, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| REBIF | Latin | Bahrain, Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.